Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | MAX | P61244 | 1/20 | 0.40 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6691557 | 0.87 | FFAR1 (0.54) | TRPA1PPARAFFAR1P2RX1ADRA2A | |
| SCHEMBL6695702 | 0.87 | TRPA1 (0.44) | AGERNPC1RAB9AMEN1KMT2A | |
| SCHEMBL6695951 | 0.86 | P2RX1 (0.46) | MEN1KMT2AMAPTTRPA1FFAR1 | |
| SCHEMBL1241369 | 0.82 | CA1 (0.45) | TRPA1PPARAFFAR1P2RX1ADRA2A | |
| SCHEMBL6696014 | 0.81 | CA1 (0.50) | TRPA1PPARAFFAR1P2RX1ADRA2A | |
| SCHEMBL6692355 | 0.80 | ADRA2A (0.49) | TRPA1PPARAFFAR1P2RX1ADRA2A | |
| SCHEMBL28383048 | 0.79 | MAPT (0.58) | NPC1RAB9AMEN1KMT2AGAA | |
| SCHEMBL6693442 | 0.76 | PTPRF (0.59) | MEN1KMT2AMAPT | |
| SCHEMBL6695962 | 0.76 | AGER (0.58) | AGERNPC1RAB9AMEN1KMT2A | |
| SCHEMBL10055021 | 0.75 | NPSR1 (0.55) | MEN1KMT2AGAAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009973-A1 | Phenylenediamine derivatives N-substituted with benzyl- or heteroarylmethyl- groups | 4SC AG (DE) | 2004-01-15 | — | — | US | disclosed |
| WO-2003076388-A2 | BIS-ANILINE DERIVATIVES USEFUL AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009973-A1 | Phenylenediamine derivatives N-substituted with benzyl- or heteroarylmethyl- groups | PAH, PNMT, OPRM1 | AGER 2404/4885NPC1 379/4885RAB9A 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.